-DOCSTART- -X- O
Application -X- _ O
of -X- _ O
highly -X- _ B-Intervention
active -X- _ I-Intervention
antiretroviral -X- _ I-Intervention
drugs -X- _ I-Intervention
( -X- _ I-Intervention
ARDs -X- _ I-Intervention
) -X- _ I-Intervention
effectively -X- _ O
reduces -X- _ O
morbidity -X- _ O
and -X- _ O
mortality -X- _ O
in -X- _ O
HIV-infected -X- _ B-Patient
individuals. -X- _ I-Patient
However -X- _ O
, -X- _ O
the -X- _ O
emergence -X- _ O
of -X- _ O
multiple -X- _ O
drug-resistant -X- _ O
strains -X- _ O
has -X- _ O
led -X- _ O
to -X- _ O
the -X- _ O
increased -X- _ O
failure -X- _ O
of -X- _ O
ARDs -X- _ O
, -X- _ O
thus -X- _ O
calling -X- _ O
for -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
anti-HIV -X- _ O
drugs -X- _ O
with -X- _ O
targets -X- _ O
or -X- _ O
mechanisms -X- _ O
of -X- _ O
action -X- _ O
different -X- _ O
from -X- _ O
those -X- _ O
of -X- _ O
the -X- _ O
current -X- _ O
ARDs. -X- _ O
The -X- _ B-Outcome
first -X- _ I-Outcome
peptide-based -X- _ I-Outcome
HIV -X- _ I-Outcome
entry -X- _ I-Outcome
inhibitor -X- _ I-Outcome
, -X- _ I-Outcome
enfuvirtide -X- _ I-Outcome
, -X- _ I-Outcome
was -X- _ I-Outcome
approved -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
U.S. -X- _ I-Outcome
FDA -X- _ I-Outcome
in -X- _ I-Outcome
2003 -X- _ I-Outcome
for -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
HIV -X- _ I-Outcome
/ -X- _ I-Outcome
AIDS -X- _ I-Outcome
patients -X- _ I-Outcome
who -X- _ I-Outcome
have -X- _ I-Outcome
failed -X- _ I-Outcome
to -X- _ I-Outcome
respond -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
current -X- _ I-Outcome
ARDs -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
has -X- _ I-Outcome
stimulated -X- _ I-Outcome
the -X- _ I-Outcome
development -X- _ I-Outcome
of -X- _ I-Outcome
several -X- _ I-Outcome
series -X- _ I-Outcome
of -X- _ I-Outcome
protein- -X- _ I-Outcome
and -X- _ I-Outcome
peptide-based -X- _ I-Outcome
HIV -X- _ I-Outcome
entry -X- _ I-Outcome
inhibitors -X- _ I-Outcome
in -X- _ I-Outcome
preclinical -X- _ I-Outcome
and -X- _ I-Outcome
clinical -X- _ I-Outcome
studies. -X- _ I-Outcome
In -X- _ O
this -X- _ O
review -X- _ O
, -X- _ O
we -X- _ O
highlighted -X- _ O
the -X- _ O
properties -X- _ O
and -X- _ O
mechanisms -X- _ O
of -X- _ O
action -X- _ O
for -X- _ O
those -X- _ O
promising -X- _ O
protein- -X- _ B-Intervention
and -X- _ I-Intervention
peptide-based -X- _ I-Intervention
HIV -X- _ I-Intervention
entry -X- _ I-Intervention
inhibitors -X- _ I-Intervention
targeting -X- _ O
the -X- _ O
HIV-1 -X- _ B-Patient
gp120 -X- _ I-Patient
or -X- _ I-Patient
gp41 -X- _ I-Patient
and -X- _ O
discussed -X- _ O
their -X- _ O
advantages -X- _ O
and -X- _ O
disadvantages -X- _ O
, -X- _ O
compared -X- _ O
with -X- _ O
the -X- _ O
current -X- _ O
ARDs -X- _ O
. -X- _ O

